Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + icotinib versus icotinib first-line treatment in EGFR-mutant advanced non-squamous NSCLC
ChiCTR-IIR-17012741Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Oct 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib and icotinib in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Guangdong Medical University. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
Rivoceranibicotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-17012741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012741.